CAS 2035509-96-5

AX-15836

CAS : 2035509-96-5

AX-15836 is an inhibitor of ERK5 (IC50 : 8 nM).

Formule : C₃₂H₄₀N₈O₅S

Degré de pureté : 98.96%

Couleur et forme : Solid

Masse moléculaire : 648.78

Ref: TM-T14360

2-[[2-Ethoxy-4-[[4-(4-methyl-1-piperazinyl)-1-piperidinyl]carbonyl]phenyl]amino]-5,11-dihydro-5-methyl-11-(methylsulfonyl)-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one

CAS : 2035509-96-5

Formule : C₃₂H₄₀N₈O₅S

Degré de pureté : 99.41%

Couleur et forme : Solid

Masse moléculaire : 648.7756

Ref: IN-DA01E3O4

AX-15836

CAS : 2035509-96-5

AX-15836

Degré de pureté : ≥98%

Masse moléculaire : 648.78g/mol

Ref: 54-BUP12689

Ax 15836

CAS : 2035509-96-5

Ax 15836

Degré de pureté : 98%

Masse moléculaire : 648.78g/mol

Ref: 54-BISN0257

AX 15836

Produit contrôlé

CAS : 2035509-96-5

Formule : C₃₂H₄₀N₈O₅S

Couleur et forme : Neat

Masse moléculaire : 648.776

Ref: TR-A965385

AX 15836

CAS : 2035509-96-5

AX 15836 is a small molecule that inhibits the transcription factor TGF-β activated kinase (TAK1) and has been shown to have synergistic activity when combined with ipatasertib, an inhibitor of the TGF-β receptor. AX 15836 is orally bioavailable and can be used for the treatment of cryptococcal meningitis. The drug has been shown to inhibit cancer cell growth in vitro and in vivo by downregulating the expression of genes involved in cancer cell proliferation. In addition, it has also been shown to reduce inflammation by inhibiting inflammatory cytokine production in a microenvironment. This agent has not been tested in pediatric patients but is effective for adults.

Formule : C₃₂H₄₀N₈O₅S

Degré de pureté : Min. 95%

Masse moléculaire : 648.78 g/mol

Ref: 3D-KGD50996